LT3200783T - Eritromelalgijos gydymas - Google Patents

Eritromelalgijos gydymas

Info

Publication number
LT3200783T
LT3200783T LTEP15790622.3T LT15790622T LT3200783T LT 3200783 T LT3200783 T LT 3200783T LT 15790622 T LT15790622 T LT 15790622T LT 3200783 T LT3200783 T LT 3200783T
Authority
LT
Lithuania
Prior art keywords
erythromelalgia
treatment
erythromelalgia treatment
Prior art date
Application number
LTEP15790622.3T
Other languages
English (en)
Inventor
Valerie MORISSET
Original Assignee
Convergence Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Convergence Pharmaceuticals Limited filed Critical Convergence Pharmaceuticals Limited
Publication of LT3200783T publication Critical patent/LT3200783T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP15790622.3T 2014-10-03 2015-10-02 Eritromelalgijos gydymas LT3200783T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1417497.3A GB201417497D0 (en) 2014-10-03 2014-10-03 Novel use
PCT/GB2015/052885 WO2016051194A1 (en) 2014-10-03 2015-10-02 Erythromelalgia treatment

Publications (1)

Publication Number Publication Date
LT3200783T true LT3200783T (lt) 2019-09-10

Family

ID=51946794

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15790622.3T LT3200783T (lt) 2014-10-03 2015-10-02 Eritromelalgijos gydymas

Country Status (14)

Country Link
US (2) US10231950B2 (lt)
EP (1) EP3200783B1 (lt)
CY (1) CY1122418T1 (lt)
DK (1) DK3200783T3 (lt)
ES (1) ES2751688T3 (lt)
GB (1) GB201417497D0 (lt)
HR (1) HRP20191434T1 (lt)
HU (1) HUE047940T2 (lt)
LT (1) LT3200783T (lt)
PL (1) PL3200783T3 (lt)
PT (1) PT3200783T (lt)
RS (1) RS59479B1 (lt)
SI (1) SI3200783T1 (lt)
WO (1) WO2016051194A1 (lt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417497D0 (en) * 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
WO2018085521A2 (en) * 2016-11-02 2018-05-11 Biogen Inc. Novel dosage regimen
CA3093401A1 (en) * 2018-04-16 2019-10-24 Biogen Ma Inc. Methods of treating neuropathic pain

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO870613L (no) 1986-03-05 1987-09-07 Molecular Diagnostics Inc Deteksjon av mikroorganismer i en prŸve inneholdende nukleinsyre.
AU632494B2 (en) 1988-05-20 1993-01-07 F. Hoffmann-La Roche Ag Immobilized sequence-specific probes
US5118801A (en) 1988-09-30 1992-06-02 The Public Health Research Institute Nucleic acid process containing improved molecular switch
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
ATE198358T1 (de) 1992-04-27 2001-01-15 Dartmouth College Detektion von gensequenzen in biologischen flüssigkeiten
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
AU699593B2 (en) 1995-02-13 1998-12-10 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
EP1288206B1 (en) 1996-04-12 2008-09-17 G.D. Searle LLC Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
US5866336A (en) 1996-07-16 1999-02-02 Oncor, Inc. Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US6117635A (en) 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
IL127441A (en) 1996-07-18 2003-02-12 Merck Frosst Canada Inc Substituted pyridines, pharmaceutical compositions comprising them and their use in the preparation of anti-inflammatory medicaments or as selective cyclooxygenase-2 inhibitors
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
CN1155600C (zh) 1997-09-05 2004-06-30 葛兰素集团有限公司 2,3-二芳基吡唑并[1,5-b]哒嗪衍生物,其制备方法和用作环氧酶2抑制剂
WO2000026216A1 (en) 1998-11-03 2000-05-11 Glaxo Group Limited Pyrazolopyridine derivatives as selective cox-2 inhibitors
US6025683A (en) 1998-12-23 2000-02-15 Stryker Corporation Motor control circuit for regulating a D.C. motor
JP2002538157A (ja) 1999-02-27 2002-11-12 グラクソ グループ リミテッド ピラゾロピリジン
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
WO2008090114A1 (en) * 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
AU2013332648B2 (en) * 2012-10-15 2017-09-07 In Therapeutics Sodium channel blockers, preparation method thereof and use thereof
EP2968307A4 (en) * 2013-03-15 2017-01-04 Purdue Pharma LP Carboxamide derivatives and use thereof
GB201409851D0 (en) * 2014-06-03 2014-07-16 Convergence Pharmaceuticals Diagnostic method
GB201417497D0 (en) * 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
KR102412146B1 (ko) * 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 소디움 채널 차단제

Also Published As

Publication number Publication date
RS59479B1 (sr) 2019-12-31
EP3200783B1 (en) 2019-07-31
CY1122418T1 (el) 2021-01-27
PT3200783T (pt) 2019-08-21
DK3200783T3 (da) 2019-08-05
EP3200783A1 (en) 2017-08-09
HRP20191434T1 (hr) 2020-10-02
HUE047940T2 (hu) 2020-05-28
ES2751688T3 (es) 2020-04-01
WO2016051194A1 (en) 2016-04-07
SI3200783T1 (sl) 2020-03-31
US20190388391A1 (en) 2019-12-26
PL3200783T3 (pl) 2020-01-31
US10231950B2 (en) 2019-03-19
GB201417497D0 (en) 2014-11-19
US20170304264A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
IL248856B (en) New treatment
IL250387A0 (en) combined treatment
GB201608885D0 (en) Treatment
GB201405033D0 (en) Combination therapy
GB201502137D0 (en) Treatment
GB201522243D0 (en) Treatment
ZA201702522B (en) Combination therapy
SG11201601030VA (en) Massager
GB201508841D0 (en) Treatment
GB201402179D0 (en) Surface treatment
HUE047940T2 (hu) Eritromelalgia kezelése
ZA201608217B (en) Combination therapy
GB201411027D0 (en) Treatment
GB201412411D0 (en) Treatment
GB201503008D0 (en) Treatment
GB201617107D0 (en) Treatment
GB201612260D0 (en) Treatment
GB201612193D0 (en) Treatment
GB201609683D0 (en) Treatment
GB201518349D0 (en) Treatment
GB201515739D0 (en) Treatment
GB201514008D0 (en) Treatment
GB201413317D0 (en) Atheroscierosis treatment
GB201412410D0 (en) Treatment
GB201400239D0 (en) Treatment